Sequence Similarity Network-Guided Discovery of a Sequence-Tolerant Cyanobactin Protease Clade for Site-Selective Peptide and Protein Modification
Journal of the American Chemical Society · 2026
DOI: 10.1021/jacs.6c14243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Yukun Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University Shenzhen Campus, She…. Hauptthemen laut MEDLINE: Peptides, Peptide Hydrolases. Die Arbeit nennt 70 Literaturangaben. Gefördert von: Shenzhen Government, China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Proteases responsible for leader peptide removal are ubiquitous in ribosomally synthesized and post-translationally modified peptide (RiPP) biosynthetic pathways. However, many characterized RiPP proteases require specific core peptide modifications prior to cleavage, limiting their broader applicability. Here, we identified a cyanobactin protease clade that efficiently processes diverse peptide substrates while maintaining strict recognition-sequence selectivity. We demonstrated that GusA, a representative member of this clade, can be used for the processing of structurally complex modified peptides and the removal of affinity tags from recombinant proteins. GusA-mediated exposure of N-terminal cysteine residues can also be applied to the construction of chemically diversified asymmetric phage-displayed macrocyclic peptide libraries, from which nanomolar-affinity ligands against Keap1 and Bcl-xL were identified, providing valuable tools for biological studies and potential therapeutics. The same strategy was further applied to site-selective and multicolor labeling of mammalian cell-surface proteins, demonstrating that GusA-mediated N-terminal cysteine generation can be readily integrated with bioorthogonal labeling chemistries. Together, our results establish cyanobactin proteases as an underexplored source of sequence-selective biocatalysts for site-selective peptide and protein modification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University Shenzhen Campus, Shenzhen518107, China.
- Institute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen518132, China.
- The Fourth Affiliated Hospital, Guangzhou Medical University, Guangzhou511300, China.
ORCID-Profile: Yang Liu, Yu-Hsuan Tsai, Yiwu Zheng
Förderung
- Shenzhen Government
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Basic Research Program of China (973 Program)
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Zhou, Y., Xiao, G., Yao, S., Zhang, Y., Yang, Y., Yang, Q., Liu, X., Wang, Y., Wu, Y., Liu, Y., Tsai, Y. H., & Zheng, Y. (2026). Sequence Similarity Network-Guided Discovery of a Sequence-Tolerant Cyanobactin Protease Clade for Site-Selective Peptide and Protein Modification. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c14243
Vancouver
Zhou Y, Xiao G, Yao S, Zhang Y, Yang Y, Yang Q, et al. Sequence Similarity Network-Guided Discovery of a Sequence-Tolerant Cyanobactin Protease Clade for Site-Selective Peptide and Protein Modification. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c14243
BibTeX
@article{Zhou2026,
author = {Zhou, Yukun and Xiao, Guangzhao and Yao, Sicong and Zhang, Yuqian and Yang, Yongqin and Yang, Qinghui and Liu, Xiaoman and Wang, Yanmei and Wu, Yapei and Liu, Yang and Tsai, Yu-Hsuan and Zheng, Yiwu},
title = {Sequence Similarity Network-Guided Discovery of a Sequence-Tolerant Cyanobactin Protease Clade for Site-Selective Peptide and Protein Modification},
journal = {Journal of the American Chemical Society},
year = {2026},
doi = {10.1021/jacs.6c14243}
}
EUVIMED